A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3361237 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2018
At a glance
- Drugs LY-3361237 (Primary) ; LY-3361237 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 21 Nov 2018 Planned End Date changed from 7 Sep 2019 to 29 Aug 2019.
- 21 Nov 2018 Planned primary completion date changed from 7 Sep 2019 to 29 Aug 2019.
- 21 Nov 2018 Status changed from not yet recruiting to recruiting.